Advertisement
New Zealand markets open in 8 hours 40 minutes

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5924
    -0.0013 (-0.21%)
     

  • NZD/EUR

    0.5540
    -0.0006 (-0.11%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.42
    -0.39 (-0.47%)
     

  • GOLD

    2,335.50
    -2.90 (-0.12%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,062.67
    +22.29 (+0.28%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,900.43
    -188.27 (-1.04%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • NZD/JPY

    92.0960
    -0.0190 (-0.02%)
     

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Zacks Equity Research
·3-min read

In the latest trading session, Moderna (MRNA) closed at $122.15, marking a -0.07% move from the previous day. This change lagged the S&P 500's daily gain of 1.97%. At the same time, the Dow added 1.88%, and the tech-heavy Nasdaq gained 0.24%.

Prior to today's trading, shares of the biotechnology company had lost 10.08% over the past month. This has lagged the Medical sector's loss of 6.47% and the S&P 500's loss of 9.93% in that time.

Moderna will be looking to display strength as it nears its next earnings release. On that day, Moderna is projected to report earnings of $5.20 per share, which would represent a year-over-year decline of 32.47%. Meanwhile, our latest consensus estimate is calling for revenue of $4.92 billion, down 1.04% from the prior-year quarter.

MRNA's full-year Zacks Consensus Estimates are calling for earnings of $26.41 per share and revenue of $22.29 billion. These results would represent year-over-year changes of -6.65% and +20.7%, respectively.

ADVERTISEMENT

Any recent changes to analyst estimates for Moderna should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.07% lower. Moderna is holding a Zacks Rank of #3 (Hold) right now.

Digging into valuation, Moderna currently has a Forward P/E ratio of 4.63. This valuation marks a discount compared to its industry's average Forward P/E of 18.82.

Also, we should mention that MRNA has a PEG ratio of 0.71. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MRNA's industry had an average PEG ratio of 1.2 as of yesterday's close.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 77, putting it in the top 31% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research